| Autor: |
Devinsky, Orrin, Honigfeld, Gilbert, Patin, John |
| Zdroj: |
Neurology (Ovid); March 1991, Vol. 41 Issue: 3 p369-371, 3p |
| Abstrakt: |
Clozapine is an atypical antipsychotic drug with minimal extrapyramidal toxicity recently approved by the Food and Drug Administration for hard-to-treat schizophrenic patients. We reviewed information on 1,418 patients treated with clozapine in the United States between 1972 and 1988. Forty-one of 1,418 (2.8) patients had generalized tonic-clonic seizures during treatment with clozapine. Life-table analysis predicts a cumulative 10 risk of seizures after 3.8 years of treatment. Clozapine-related seizures appear to be dose-related. High-dose therapy (≥600 mg/day) was associated with a greater risk of seizures (4.4) than medium (300 to 600 mg/day; 2.7) or low doses ((<300 mg/day; 1.0). Also, rapid upward titration may increase seizure risk. Thirty-one of 41 patients were successfully continued on clozapine despite seizure occurrence, either with reduction of dose or addition of an antiepileptic medication. Recognition and treatment of clozapine-related seizures will become increasingly important as its use grows in the 1990s. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
